We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Accuracy of TCD Monitoring in Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2013 by Liu Bao, Peking Union Medical College Hospital.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01799070
First Posted: February 26, 2013
Last Update Posted: February 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Liu Bao, Peking Union Medical College Hospital
  Purpose

Background: Cerebral hyperperfusion syndrome (CHS) is a life threatening complication of carotid endarterectomy (CEA) and the changes of middle cerebral artery velocity are used to predict the occurrence of CHS but the accuracy is limited. In addition, changes of BP post-operatively comparing with baseline BP should be a predictive factor of CHS.

Objective: The investigators aimed to create a predictive index, velocity systolic blood pressure index (VSI), for improving the predictive power of Transcranial Doppler monitoring regarding CHS.

Methods: The study design is a diagnostic test, which is an observational analytic clinical study. From March 2013 to September 2014, 200 patients will be recruited. Patients will be classified according to the CHS occurrence. VSI combined the changes of middle cerebral artery velocity and blood pressure crossing CEA and the intra- and post-operative increase ratios of middle cerebral artery velocity were calculated. Their prediction power of CHS will be compared. Sensitivity, specificity, positive predictive value, negative predictive value of them will be calculated. Receiver operating characteristic analysis will be performed.

Expected Outcomes: Comparing with the commonly used intra-operative and post-operative TCD monitoring, VSI may be more useful to select CHS in patients who underwent CEA. As far as the investigators know, analysis or studies combining the BP and velocity changes in the prediction of CHS have never been performed.


Condition
Carotid Stenosis Cerebral Hyperperfusion Syndrome Blood Pressure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Velocity Systolic Blood Pressure Index in Accurately Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy

Further study details as provided by Liu Bao, Peking Union Medical College Hospital:

Primary Outcome Measures:
  • cerebral hyperperfusion syndrome [ Time Frame: within 7 days after surgery ]
    CHS will be diagnosed if (1) the patient developed symptoms that ipsilateral moderate or severe headache, confusion, seizures, intracranial hemorrhage or focal neurological deficits after a symptom-free interval. (2) symptoms not secondary to cerebral ischemia which will be excluded by CT or MRI. (3) MCAV increasing >100% from baseline which identified by TCD. (4) within 7 days after surgery. (5) An independent neurologist made the diagnosis of CHS.


Estimated Enrollment: 200
Study Start Date: March 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)

Detailed Description:
This study is designed as a standard diagnostic test. It is designed to verify the predictive power of VSI with CHS, and which is an observational analytic clinical study. The investigative parameters of patients will be collected prospectively by the designed case report form. According to the incidence of CHS, the estimated enrollment amount is set as 200. Patients will be recruited by the inclusion and exclusion criteria below. All the patients included will accept the standard CEA surgery treatment in the department of vascular surgery of PUMCH. MCAV and systolic BP data will be recorded cross CEA. Post-operatively the CHS patients will be identified according to the golden standard. The golden standard is the clinical diagnose of CHS (the detailed diagnostic criteria will be stated in the methodology part). The TCD operator is blind to the patients. The predictive power of VSI will be identified by the sensitivity, specificity, positive predictive value, negative predictive value and ROC plot comparing with the golden standard. The study start date is March 2013, the estimated study completion date is December 2014 and the primary completion date is September 2014 (final data collection date for primary outcome measure).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who with carotid stenosis will accept CEA in PUMCH from March 2013 to September 2014.
Criteria

Inclusion Criteria:

  1. Age from 30 to 85 years;
  2. Had a middle-grade symptomatic carotid stenosis (more than 50%) or a high-grade asymptomatic carotid stenosis (more than 70%);
  3. Underwent CEA 30 days after the last ischemic cerebrovascular event in the case of symptomatic carotid stenosis;
  4. Signed the ethical information consent form
  5. Underwent TCD study intraoperative and immediately after CEA;
  6. The degree of carotid stenosis will be assessed by CT angiography or cerebral digital subtraction angiography (DSA). (The method document came from the North American Symptomatic Carotid Endarterectomy Trial study.)

Exclusion Criteria:

  1. Emergency CEA within 30 days of stroke onset in the case of symptomatic carotid stenosis;
  2. No temporal windows to measure the MCAV.
  3. Restenosis after CEA or CAS
  4. Stenosis caused by non-atherosclerotic diseases
  5. Combined severe systematic diseases that markedly decrease the life cycle
  6. Allergy to medicines of the study such as Aspirin or Statin
  7. Refuse to sign the ethical information consent form
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01799070


Contacts
Contact: Bao Liu, MD +86-10-88068230 liubao72@yahoo.com.cn

Locations
China, Beijing
vascular surgery department of PUMCH Not yet recruiting
Beijing, Beijing, China, 100730
Principal Investigator: Bao Liu, MD         
Principal Investigator: Changwei Liu, MD         
Sub-Investigator: Zhichao Lai, MD         
Sponsors and Collaborators
Peking Union Medical College Hospital
  More Information

Responsible Party: Liu Bao, M.D., Peking Union Medical College Hospital
ClinicalTrials.gov Identifier: NCT01799070     History of Changes
Other Study ID Numbers: PUMCH-20130113
B2009B080 ( Other Grant/Funding Number: Central Committee of China health care Administration )
First Submitted: February 24, 2013
First Posted: February 26, 2013
Last Update Posted: February 26, 2013
Last Verified: February 2013

Keywords provided by Liu Bao, Peking Union Medical College Hospital:
Prediction
Transcranial Doppler

Additional relevant MeSH terms:
Syndrome
Carotid Stenosis
Disease
Pathologic Processes
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases